Citius Pharma Q3 10-Q: $49.4M Loss, Cash Runway to November, Going Concern

summarizeSummary

Citius Pharma's Q3 10-Q reveals a $49.4M nine-month loss, cash runway only to November 2026, and a going concern warning, alongside a $19.7M CMO termination fee and Nasdaq listing challenges.

check_boxKey Events · Earnings and Guidance · CTXR

• Going Concern Warning

  Cash of $17.0 million and negative working capital of $8.3 million fund operations only through November 2026, raising substantial doubt about the company's ability to continue as a going concern.

• Nine-Month Net Loss

  Net loss of $49.4 million for the nine months ended June 30, 2026, driven by a $19.7 million contract cancellation fee from a CMO termination and increased commercial expenses.

• Nasdaq Listing Non-Compliance

  Both Citius Pharma and Citius Oncology received Nasdaq notices for failing to maintain a $1.00 minimum bid price; Citius Pharma's compliance deadline was August 10, 2026, and it has requested an extension.

• Term Loan and Warrants

  Citius Oncology entered a $25 million term loan with $10 million funded, bearing interest at prime + 6% or 12.75%, secured by all assets, and issued warrants to purchase 1,111,111 shares at $0.90.

auto_awesomeAnalysis · CTXR · Life Sciences

Citius Pharmaceuticals reported a net loss of $49.4 million for the nine months ended June 30, 2026, with only $17 million in cash and negative working capital of $8.3 million. Management states cash will fund operations only through November 2026, raising substantial doubt about the company's ability to continue as a going concern. The quarter also included a $19.7 million contract cancellation fee from a CMO termination, and the company faces Nasdaq delisting notices for both itself and its subsidiary Citius Oncology. While LYMPHIR revenue is growing, it remains insufficient to offset heavy operating losses and debt obligations.